Botox and Dysport Both Doing Well in Competitive Market

Allergan and Medicis are showing increased profits this quarter, and analysts are partially attributing the growth to third quarter BOTOX® and Dysport® sales.

According to CNN Money , revenues for Dysport® manufacturer Medicis last quarter are 30 percent above last year’s figures.  “We are encouraged by the positive physician and patient response to DYSPORT” said Medicis CEO Jonah Shacknai.

While other products may have played a role, Dysport® sales were a major factor.  Yet, the new drug still didn’t manage to hurt sales of BOTOX®, the only competitor on the market right now.

Aided by a 3 percent increase in BOTOX® sales, “Allergan’s third quarter profit rose 8.3 percent” reports the Wall Street Journal. New treatment applications are also in the works, which would likely drive sales further.

Although there’s been a positive response to Dysport® in Little Rock , the brand awareness of BOTOX® is still a major factor affecting sales, and that probably won’t change anytime soon.